



EXPRESS MAIL NO. EV335549255US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robin Callan et al.
Application No. : 09/667,489
Filed : September 22, 2000
For : HIGH CITRATE DIALYSATE AND USES THEREOF
Examiner : Patricia Bianco
Art Unit : 3762
Docket No. : 100070.402
Date : May 9, 2005

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. A Copy of the cited U.S. patent is not required and accordingly has not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 CFR 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Carol J. Roth
Registration No. 32,783

CJR:ljt

Enclosures:

Form PTO-1449
Cited References (10)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

\589804


FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

100070.402

APPLICATION NO.

09/667,489

THIRD SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robin Callan

FILING DATE

September 22, 2000

GROUP ART UNIT

3762

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,610,206	08/26/03	Callan et al.	210	646	
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AG	JP 10-87478 A	04/07/98	Japan		X
	AH	JP 10-87478 A	04/07/98	Japan	X	
	AI	WO 99/07419	02/18/99	WIPO		
	AJ	WO 00/23086	04/27/00	WIPO		
	AK					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Gupta, A. et al., "Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis," <i>Kidney International</i> 55(5): 1891-1898, May 1999.
	AM	Křížek, M. et al., "Influence of Hemodialysis on Selenium Blood Levels," <i>Sborník lékařský</i> 101(3): 241-248, 2000.
	AN	Napolitano, G. et al., "Thyroid Function and Plasma Selenium in Chronic Uremic Patients on Hemodialysis Treatment," <i>Biological Trace Element Research</i> 55(1/2): 221-230, October/November 1996.
	AO	Zima, T. et al., "Trace Elements in Hemodialysis and Continuous Ambulatory Peritoneal Dialysis Patients," <i>Blood Purification</i> 16(1): 253-260, January-February 1998.
	AP	Zima, T. et al., "Trace Elements in End-Stage Renal Disease," <i>Blood Purification</i> 17(1): 187-198, 1999.
	AQ	"NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure," <i>American Journal of Kidney Diseases</i> 30(4 Suppl. 3): S192-S240, October 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).